These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

321 related articles for article (PubMed ID: 23845143)

  • 21. Radiotherapy Synergizes with the Hypoxia-Activated Prodrug Evofosfamide: In Vitro and In Vivo Studies.
    Takakusagi Y; Kishimoto S; Naz S; Matsumoto S; Saito K; Hart CP; Mitchell JB; Krishna MC
    Antioxid Redox Signal; 2018 Jan; 28(2):131-140. PubMed ID: 28741367
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Design, synthesis, and biological evaluation of indolequinone phosphoramidate prodrugs targeted to DT-diaphorase.
    Hernick M; Flader C; Borch RF
    J Med Chem; 2002 Aug; 45(16):3540-8. PubMed ID: 12139465
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Identification of P450 Oxidoreductase as a Major Determinant of Sensitivity to Hypoxia-Activated Prodrugs.
    Hunter FW; Young RJ; Shalev Z; Vellanki RN; Wang J; Gu Y; Joshi N; Sreebhavan S; Weinreb I; Goldstein DP; Moffat J; Ketela T; Brown KR; Koritzinsky M; Solomon B; Rischin D; Wilson WR; Wouters BG
    Cancer Res; 2015 Oct; 75(19):4211-23. PubMed ID: 26297733
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Targeting hypoxia with a new generation of indolequinones.
    Jaffar M; Naylor MA; Robertson N; Stratford IJ
    Anticancer Drug Des; 1998 Sep; 13(6):593-609. PubMed ID: 9755720
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Evofosfamide, a new horizon in the treatment of pancreatic cancer.
    Pourmorteza M; Rahman ZU; Young M
    Anticancer Drugs; 2016 Sep; 27(8):723-5. PubMed ID: 27232101
    [TBL] [Abstract][Full Text] [Related]  

  • 26. An Intratumor Pharmacokinetic/Pharmacodynamic Model for the Hypoxia-Activated Prodrug Evofosfamide (TH-302): Monotherapy Activity is Not Dependent on a Bystander Effect.
    Hong CR; Wilson WR; Hicks KO
    Neoplasia; 2019 Feb; 21(2):159-171. PubMed ID: 30591421
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Benzotriazine Di-Oxide Prodrugs for Exploiting Hypoxia and Low Extracellular pH in Tumors.
    Hay MP; Shin HN; Wong WW; Sahimi WW; Vaz ATD; Yadav P; Anderson RF; Hicks KO; Wilson WR
    Molecules; 2019 Jul; 24(14):. PubMed ID: 31295864
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Chemotherapy Rescues Hypoxic Tumor Cells and Induces Their Reoxygenation and Repopulation-An Effect That Is Inhibited by the Hypoxia-Activated Prodrug TH-302.
    Saggar JK; Tannock IF
    Clin Cancer Res; 2015 May; 21(9):2107-14. PubMed ID: 25677696
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The 2-nitroimidazole EF5 is a biomarker for oxidoreductases that activate the bioreductive prodrug CEN-209 under hypoxia.
    Wang J; Foehrenbacher A; Su J; Patel R; Hay MP; Hicks KO; Wilson WR
    Clin Cancer Res; 2012 Mar; 18(6):1684-95. PubMed ID: 22167409
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Bystander effects of bioreductive drugs: potential for exploiting pathological tumor hypoxia with dinitrobenzamide mustards.
    Wilson WR; Hicks KO; Pullen SM; Ferry DM; Helsby NA; Patterson AV
    Radiat Res; 2007 Jun; 167(6):625-36. PubMed ID: 17523848
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Hypoxia-selective agents derived from quinoxaline 1,4-di-N-oxides.
    Monge A; Palop JA; López de Ceráin A; Senador V; Martínez-Crespo FJ; Sainz Y; Narro S; García E; de Miguel C; González M
    J Med Chem; 1995 May; 38(10):1786-92. PubMed ID: 7752202
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Hypoxia-Activated Prodrug TH-302 Targets Hypoxic Bone Marrow Niches in Preclinical Leukemia Models.
    Benito J; Ramirez MS; Millward NZ; Velez J; Harutyunyan KG; Lu H; Shi YX; Matre P; Jacamo R; Ma H; Konoplev S; McQueen T; Volgin A; Protopopova M; Mu H; Lee J; Bhattacharya PK; Marszalek JR; Davis RE; Bankson JA; Cortes JE; Hart CP; Andreeff M; Konopleva M
    Clin Cancer Res; 2016 Apr; 22(7):1687-98. PubMed ID: 26603259
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Enzymatic activation of indolequinone-substituted 5-fluorodeoxyuridine prodrugs in hypoxic cells.
    Jiho Y; Kurihara R; Kawai K; Yamada H; Uto Y; Tanabe K
    Bioorg Med Chem Lett; 2019 Jun; 29(11):1304-1307. PubMed ID: 30975626
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The role of human and rodent DT-diaphorase in the reductive metabolism of hypoxic cell cytotoxins.
    Walton MI; Sugget N; Workman P
    Int J Radiat Oncol Biol Phys; 1992; 22(4):643-7. PubMed ID: 1544831
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Hypoxia-selective antitumor agents. 16. Nitroarylmethyl quaternary salts as bioreductive prodrugs of the alkylating agent mechlorethamine.
    Tercel M; Lee AE; Hogg A; Anderson RF; Lee HH; Siim BG; Denny WA; Wilson WR
    J Med Chem; 2001 Oct; 44(21):3511-22. PubMed ID: 11585455
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The flavoprotein FOXRED2 reductively activates nitro-chloromethylbenzindolines and other hypoxia-targeting prodrugs.
    Hunter FW; Jaiswal JK; Hurley DG; Liyanage HD; McManaway SP; Gu Y; Richter S; Wang J; Tercel M; Print CG; Wilson WR; Pruijn FB
    Biochem Pharmacol; 2014 May; 89(2):224-35. PubMed ID: 24632291
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Bioreductive drugs: from concept to clinic.
    McKeown SR; Cowen RL; Williams KJ
    Clin Oncol (R Coll Radiol); 2007 Aug; 19(6):427-42. PubMed ID: 17482438
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Nitro-chloromethylbenzindolines: hypoxia-activated prodrugs of potent adenine N3 DNA minor groove alkylators.
    Wilson WR; Stribbling SM; Pruijn FB; Syddall SP; Patterson AV; Liyanage HD; Smith E; Botting KJ; Tercel M
    Mol Cancer Ther; 2009 Oct; 8(10):2903-13. PubMed ID: 19808982
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Hypoxia-activated prodrug TH-302 decreased survival rate of canine lymphoma cells under hypoxic condition.
    Yamazaki H; Lai YC; Tateno M; Setoguchi A; Goto-Koshino Y; Endo Y; Nakaichi M; Tsujimoto H; Miura N
    PLoS One; 2017; 12(5):e0177305. PubMed ID: 28489881
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Oxygen dependence and extravascular transport of hypoxia-activated prodrugs: comparison of the dinitrobenzamide mustard PR-104A and tirapazamine.
    Hicks KO; Myint H; Patterson AV; Pruijn FB; Siim BG; Patel K; Wilson WR
    Int J Radiat Oncol Biol Phys; 2007 Oct; 69(2):560-71. PubMed ID: 17869669
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.